[Antifungal drugs for pediatric use].
There are no specialized formulations of antifungal drugs in Japan which are prepared for children. Modification of the therapeutic doses by age groups or by body weight of the patients from the recommended doses for adults as well as special precautions against side effects are needed for pediatric use. Reports focusing on the side effects of topical and systemic antifungal drugs are reviewed. All the newly introduced systemic drugs, such as fluconazole, itraconazole and terbinafine, have been well tolerated during the treatment of fungal infections of neonates and infants.
Nishimoto
K
K
Division of Dermatology, Nagasaki Municipal Hospital, Shinchi-machi 6-39, Nagasaki 850-8555, Japan.
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D015725:Fluconazole; D000077291:Terbinafine